Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial
G Viale, FA De Snoo, L Slaets, J Bogaerts… - Breast cancer research …, 2018 - Springer
G Viale, FA De Snoo, L Slaets, J Bogaerts, L van 't Veer, EJ Rutgers, MJ Piccart-Gebhart…
Breast cancer research and treatment, 2018•SpringerPurpose This study compares immunohistochemical (IHC) versus molecular subtyping
(BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome
based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined
by the 2013 St. Gallen guidelines. Methods MS classified patients in the following subtypes:
Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER,
PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology (n …
(BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome
based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined
by the 2013 St. Gallen guidelines. Methods MS classified patients in the following subtypes:
Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER,
PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology (n …
Purpose
This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined by the 2013 St. Gallen guidelines.
Methods
MS classified patients in the following subtypes: Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER, PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology (n = 5806). Hazard ratios for distant-metastasis-free survival (DMFS) by subtype were adjusted for chemotherapy and endocrine therapy administration and thus independent of adjuvant treatment allocation.
Results
PS Luminal cancers classified as HER-2+ or Basal-type by MS did not have a significantly lower DMFS than the Luminal-type cancers by MS (95.9%): HR = 1.40, 95% CI 0.75–2.60 (p = 0.294). More patients were identified with Luminal A disease by MS (63%) as compared with PS (47%) with comparable 5-year DMFS (≥96.0%). Among the 500 patients with PS TN cancers, MS identified 24 (5%) patients as Luminal-type with 5-year DMFS estimated at 100% versus 71.4% for MS HER-2+ or 90.1% for MS Basal-type.
Conclusions
MS was able to re-stratify 54% of patients with a Luminal-B PS subtype to a low-risk Luminal A-type group with comparable outcome. Among TN EBC, 5% were classified as Luminal by MS with Luminal-like outcome. Molecular classification can help to identify a larger group of patients with low risk of recurrence compared with the more contemporarily used classification methodology including high-quality assessed Ki67.
Springer
